DNA synthesis companies currently perform safety screening on sequences submitted by customers. One important method is comparing new orders against known pathogens, toxins, and other potentially risky biological sequences, and when highly similar content is found, further verifying the customer's identity and purpose. The premise of this process is that an unfamiliar sequence either can be matched in a database or has identifiable similarity to a known dangerous sequence.
Generative AI is shaking this premise. AI can actively design new proteins that have never existed in nature, and even if two proteins differ greatly in amino acid sequence, they may still form similar structures and achieve similar functions. This means a protein redesigned by AI may show almost no obvious sequence connection to a known dangerous protein, yet still have similar functions. Faced with such an unfamiliar sequence, relying only on database comparison makes it increasingly difficult to determine whether it comes from a natural organism, normal scientific design, or an artificially designed potentially risky sequence.
What SynthID Bio aims to provide is precisely this additional piece of provenance information. It cannot directly prove a protein is safe or dangerous; rather, it tells screeners where this design came from.